Xencor Inc
Xencor, Inc. (Nasdaq: XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune and inflammatory diseases. Its XmAb protein-engineering technologies modify antibody Fc domains and support multi-specific formats designed to engage multiple… From the company’s description.
Over the twelve months to Sep 30, 2026, Xencor Inc reported revenue of $200.49M, up 33.5% from a year earlier, and a net loss of $117.86M. Its operating margin was −72.7%, and operations used $172.35M in cash. In fiscal 2025, it reported revenue of $125.58M, up 13.7% from fiscal 2024, and a net loss of $92.14M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Xencor Inc does
In the company’s own words
Xencor, Inc. (Nasdaq: XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune and inflammatory diseases. Its XmAb protein-engineering technologies modify antibody Fc domains and support multi-specific formats designed to engage multiple targets, alter immune activity, or extend drug half-life. Xencor advances its own candidates through early clinical development and licenses technologies and drug candidates to pharmaceutical and biotechnology partners, which conduct further development and may commercialize resulting medicines. Its wholly owned clinical programs include candidates for solid tumors, inflammatory bowel disease, rheumatoid arthritis, and inflammatory myopathies; partnered programs include oncology, autoimmune, and infectious-disease therapies. The company reports one business segment and generates revenue through licensing and collaboration arrangements, including milestone payments and royalties. Three marketed medicines have been developed using XmAb technologies: Monjuvi, Minjuvi, and Ultomiris. As of December 31, 2025, Xencor had 260 full-time employees, including 212 in research and development. Its website is www.xencor.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PASADENA, CA
- Fiscal year end
- December
- CIK
- 1326732
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Xencor Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Xencor Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Xencor Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Xencor Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Xencor Inc's last four quarterly filings that the numbers alone won't show?”